Antiretroviral Treatment in Correctional Facilities

REFERENCES

• Hogg RS, EaIt KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279:450–454.
   PubMed Web of Science ®Google Scholar
• PaleIla FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced hu-man immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–860.
   PubMed Web of Science ®Google Scholar
• Hogg RS, Yip B, KuIly C, et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ. 1999;160:659–665.
   PubMed Web of Science ®Google Scholar
• Floridia M, MasseIla M, Bucciardini R, et al. Hospitalizations and costs of treatment for protease inhibitor-based regi-mens in patients with very advanced HIV-infection (CD4 < 50/mm3). HIV Clin Thais. 2000;1:9–16.
   PubMedGoogle Scholar
• Lavalle C, Aguilar JC, Pena F, Estrada-Aguilar JL, Avina-Zubieta JA, Madrazo M. Reduction in hospitalization costs, morbidity, disability, and mortality in patients with AIDS treated with protease inhibitors. Arch Med Res. 2000;31:515–519.
   PubMed Web of Science ®Google Scholar
• Palepu A, Yip B, Miller C, et al. Factors associated with the response to antiretroviral therapy among HIV-infected pa-tients with and without a history of injection drug use. AIDS. 200115: 423–424.
   Google Scholar
• Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81–87.
   PubMed Web of Science ®Google Scholar
• Moreno A, Perez-Elias MJ, Casado JL, et al. Long-term outcomes of protease inhibitor-based therapy in antiretroviral treatment-naive HIV-infected injection drug us-ers on methadone maintenance programmes. AIDS. 200115: 1068–1070.
   Google Scholar
• Jensen-Fangel S, Pedersen L, Pedersen C, et al. The effect of race/ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency virus type 1-infected patients. Clin Infect Dis. 2002;35:1541–1548.
   PubMed Web of Science ®Google Scholar
• Palepu A, Tyndall MW, Li K, et al. Alcohol use and incarcera-tion adversely affect HIV-1 RNA suppression among injec-tion drug users starting antiretroviral therapy. J Urban Health: Bull NY Acad Med. 2003;80(4):667–675.
   PubMed Web of Science ®Google Scholar
• Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS. 2004;18(6):887–895.
   PubMed Web of Science ®Google Scholar
• Palombi L, Narciso P, Perno CF, et al. One year of HAART in Mozambique: survival, virological, and immunological re-sults of DREAM project in adults and children. In: Program and abstracts of the XI Conference on Retroviruses and Opportunistic Infections; February, 8–11, 2004; San Fran-cisco, California. Abstract 148.
   Google Scholar
• UNAIDS. Pr/sons and AIDS: UNAIDS Point of View. Geneva, Switzerland: Author; 1997.
   Google Scholar
• Repubblica Italiana. Ministero della Giustizia. Dipartimento dell'Amministrazione Penitenziaria. Indagine nazionale sui detenuti tossicodipendenti e affetti da virus HIV; rilevamento al 31/12/2001. Rome, Italy: Ministry of Justice; 2002.
   Google Scholar
• Commissione nazionale per la lotta contro l'AIDS e le altre malattie infettive emergenti e riemergenti. L'infezione da HIV nell'ambito degli istituti penitenziari. Rome, Italy: Ministero della Salute; December 18,2003.
   Google Scholar
• Long J, Allwright S, Barry J, et al. Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in entrants to Irish prisons: a national cross sectional survey. BMJ. 2001323: 1–6.
   Google Scholar
• Maruschak LM. Bureau of Justice Statistics Bulletin: HIV in Prisons and Jails, 1999. Document NCJ 187456, 2001. Available at: http://www.ojp.usdoj.gov/bjs/abstract/hivpj99.htm. Accessed September 20, 2004.
   Google Scholar
• Maruschak LM. HIV in Prisons, 2001. Bureau of Justice Statistics, Bulletin. US Department of Justice, Office of Justice Programs; January 2004. Available at: http://www.ojp.usdoj.gov/bjs/abstract/hivp01.htm. Accessed September 20, 2004.
   Google Scholar
• Guimaraes T, Granato CF, Varella D, Ferraz ML, Castelo A, Kailas EG. High prevalence of hepatitis C infection in a Brazilian prison: identification of risk factors for infection. Braz J Infect Dis. 2001;5(3):111–118.
   PubMedGoogle Scholar
• Thaisri H, Lerwitworapong J, Vongsheree S, et al. HIV infection and risk factors among Bangkok prisoners, Thai-land: a prospective cohort study. BMC Infect Dis. 2003;3:25.
   PubMed Web of Science ®Google Scholar
• WHO-EURO. HIV in Prisons. A Reader with Particular Rel-evance to the Newly Independent States. Copenhagen, Denmark: Author; 2001.
   Google Scholar
• Hammett TM, Harmon MP, Rhodes W. The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997. Am J Public Health. 2002;92:1789–1794.
   PubMed Web of Science ®Google Scholar
• Hammet, TM. Public Health/Corrections Collaborations: Prevention and Treatment of HIV/AIDS, STDs, and TB. Washington, DC: National Institute of Justice; 1998.
   Google Scholar
• Altice FL, Mostashari F, Friedland GH. Trust and the ac-ceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;28:47–58.
   PubMed Web of Science ®Google Scholar
• Dublin declaration on HIV/AIDS in prisons in Europe and Central Asia: Prison health is public health. Dublin, Ireland. February 23, 2004. Available at: http://www.euro.who.int/eprise/main/who/progs/HIPP/Home. Accessed August, 31 2004.
   Google Scholar
• UNAIDS. Pr/sons and AIDS: UNAIDS Technical Update. Geneva, Switzerland: Author; 1997.
   Google Scholar
• Spaulding A, Stephenson B, Macalino G, Ruby W, Clarke JG, Flanigan TP. Human immunodeficiency virus in correc-tional facilities: a review. Clin Infect Dis. 2002;35:305–312.
   PubMed Web of Science ®Google Scholar
• Mostashari F, Riley E, Selwyn PA, Altice FL. Acceptance and adherence with antiretroviral therapy among HIV-in-fected women in a correctional facility. J Acquir Immune Defic Syndr Hum RetroviroL 1998;18(4):341–348.
   PubMedGoogle Scholar
• Baillargeon J, Borucki MJ, Zepeda S, Jenson HB, Leach CT. Antiretroviral prescribing patterns in the Texas prison system. Clin Infect Dis. 2000;31:1476–1481.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Guidelines for a Public Health Approach, 2003 revision. Geneva, Switzer-land: WHO; December 2003.
   Google Scholar
• Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. March 23, 2004. Available at: http://www.aidsinfo.nih.gov//guidelines/adult/AA_032304.pdf. Accessed September 20,2004.
   Google Scholar
• Estelle v. Gamble, 429 US 97 (Supreme Court 1976); USA.
   Google Scholar
• Judge says prison must obey NIH treatment guidelines. National Institute of Health. AIDS Policy Law. 1999;14(14):1–8.
   Google Scholar
• Frank L. Prisons and public health: emerging issues in HIV treatment adherence. J Assoc Nurses AIDS Care. 1999;10(6):24–32.
   PubMedGoogle Scholar
• Griffin MM, Ryan JG, Briscoe VS, Shadle KM. Effects of incarceration on HIV-infected individuals. J Natl Med Assoc. 1996;88:639–644.
   PubMed Web of Science ®Google Scholar
• Hubbard M., Piliero PJ, Moehs CJ, Battaglioli-DeNero A, eds. Nursing Care of the HIV-Infected Inmate Learning Module 3: Adherence & Resistance. Albany, NY: Albany Medical Center Hospital; 2003.
   Google Scholar
• Gallego O, Corral A, de Mendoza C, González-Lahoz Juan, Soriano V. High rate of resistance to antiretroviral drugs among HIV-infected prison inmates. Med Sc/ Mon/t. 2003;9(6):CR269–273.
   Google Scholar
• Samet JH, Libman H, Steger KA, et al. Compliance with zidovudine therapy in patients infected with human im-munodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic. Am J Med. 1992;92:495–501.
   PubMed Web of Science ®Google Scholar
• Muma RD, Ross MW, Parcel GS, Pollard RB. Zidovudine adherence among individuals with HIV infection. AIDS Care. 1995;7:439–447.
   PubMed Web of Science ®Google Scholar
• O'Connor PG, Molde S, Henry S, Shockcor WT, Schottenfeld RS. Human immunodeficiency virus infec-tion in injection drug users: a model for primary care. Am J Med. 1992;93:382–386.
   PubMed Web of Science ®Google Scholar
• Selwyn PA, Budner NS, Wasserman WC, Arno PS. Utili-zation of on-site primary care services by HIV-seroposi-tive and seronegative drug users in a methadone mainte-nance program. Public Health Rep. 1993;108:492–500.
   PubMed Web of Science ®Google Scholar
• Solomon L, Vlahov D, Astemborski J, Galai N, Graham NMH, Nelson KE. Factors associated with initiation of zidovudine in a cohort of injection drug users. J Drug Issues. 1995;25:225–233.
   Web of Science ®Google Scholar
• Wohl DA, Stephenson BL, Golin CE, et al. Adherence to directly observed antiretroviral therapy among human im-munodeficiency virus-infected prison inmates. Clin Infect Dis. 2003;36:1572–1576.
   PubMed Web of Science ®Google Scholar
• Babudieri S, D'Offizi GP, Carbonara S, Starnini G. Directly observed therapy to treat HIV infection in prisoners. JAMA. 2000;284(2)1 79–180.
   PubMed Web of Science ®Google Scholar
• Marco A, Cayla JA, Serra M, et al. Predictors of adher-ence to tuberculosis treatment in a supervised therapy programme for prisoners before and after release. Study Group of Adherence to Tuberculosis Treatment of Prison-ers. Eur Respir J. 1998;12(4):967–971.
   PubMed Web of Science ®Google Scholar
• Wood E, Montaner JSG, Bangsberg DR, et al. Expanding access to HIV antiretroviral therapy among marginalized populations in the developed world. AIDS. 2003;17(17): 2419–2427.
   PubMed Web of Science ®Google Scholar
• White MC, Mehrotra A, Menendez E, Estes M, Goldenson J, Tulsky JP. Jail inmates and HIV care: provision of antiretroviral therapy and Pneumocystis carinii pneumo-nia prophylaxis. Int J STD AIDS. 2001;12(6):380–385.
   PubMed Web of Science ®Google Scholar
• Kim JY, Rich J, Zeiler S, et al. Successful community follow-up and reduced recidivism of HIV positive women prisoners. J Correctional Health Care. 1997;4:1–9.
   Google Scholar
• Flanigan TP, Kim JY, Zierler S, Rich JD, Vigilante K, Bury-Maynard D. A prison release program for HIV-positive women: linking them to health services and community follow-up. Am J Public Health. 1996;86:886–887.
   PubMed Web of Science ®Google Scholar
• Skolnick AA. Correctional and community health care collaborations. JAMA. 1998;279:98–99.
   PubMed Web of Science ®Google Scholar
• Wohl DA, Stephenson BL, Strauss R, et al. Access to HIV care and antiretroviral therapy following release from prison. In: Program and abstract of XI Conference on Retroviruses and Opportunistic Infections; February, 8–11, 2004; San Francisco, California. Abstract 859.
   Google Scholar
• Howard TR, Campbell WA. Positive tools for HIV+ prison-ers. In: Program and abstract of XV International AIDS Conference; July, 11–16, 2004; Bangkok, Thailand. Ab-stract number: WePeE6856.
   Google Scholar
• Kennedy SS, Hammett TM, Braithwaite R, Arriola KRJ. Improving access to and utilization of health and social services for HIV-infected jail and prison releasees: evalu-ation results from the Corrections Demonstration Project funded by the Centers For Disease Control and Preven-tion (CDC) and Health Resources and Services Adminis-tration (HRSA). In: Program and abstract of XV Interna-tional AIDS Conference; July, 11–16, 2004; Bangkok, Thailand. Abstract ThPeE7996.
   Google Scholar
• Babudieri S, Starnini G, Brunetti B, et al. HIV e infezioni correlate negli Istituti Penitenziari ItaHank note di epidemiologia e di organizzazione sanitaria. Ann 1st Super Sanita. 2003;39(2):251–257.
   Google Scholar
• Garcia-Guerrero J, Herrero A, Bedia M, Araujo R, Castellano JC. Grupo de Estudio REPRICOVA. Resistencias primarias de VIH en una población penitenciaria. Estudio REPRICOVA-2. Enferm Infecc Microbiol Cl/n. 2004;22:29–31.
   PubMed Web of Science ®Google Scholar
• Kirkland LR, Fisch! MA, Tashima KT, et al. for the NZTA4007 Study Team. Response to Lamivudine-Zidovudine plus Abacavir twice daily in antiretroviral-na-ive, incarcerated patients with HIV infection taking di-rectly observed treatment. Clin Infect Dis. 2002;34:511–518.
   PubMed Web of Science ®Google Scholar
• Europe Council. Recommandation N.R. (93) 6 du Comité des Ministres aux Etats membres concernant les aspects pénitentiaires et criminologiques du contrôle des mala-dies transmissible et notamment du SIDA, et les problemes connexes de sante en prison. 1993.
   Google Scholar
• Palmiere C, Toscanini F. La normative italiana in materia di AIDS. Istituto Italiano di Medicina Sociale. Rome, Italy; 2004.
   Google Scholar